Annabel Samimy

Douglas Tsao

Navann Ty

Serge Belanger

Madhumita Yennawar

Marc Goodman

Sam Eiber

Uy Ear

Charles

Doug Tsao

Mikaela Franceschina

Navann Ty Dietschi

- Evolus announced **positive topline results** from a U.S. pivotal study for its Evolysse™ Sculpt injectable hyaluronic acid gel product, demonstrating **statistical superiority to Restylane®-Lyft**.  **[1570562_afdbb753a36b48788f774140deb56f3f_0]** **[1570562_afdbb753a36b48788f774140deb56f3f_1]** 
- The **Premarket Approval (PMA) application** for Evolysse™ Sculpt has been submitted to the U.S. Food and Drug Administration (FDA), with **approval expected in the second half of 2026**.  **[1570562_afdbb753a36b48788f774140deb56f3f_0]** **[1570562_afdbb753a36b48788f774140deb56f3f_1]** 
- Evolysse™ Sculpt is anticipated to be the **flagship brand** in the Evolysse™ collection, expanding Evolus's portfolio beyond Jeuveau® and targeting the highest-value segment of the dermal filler market.  **[1570562_afdbb753a36b48788f774140deb56f3f_0]** **[1570562_afdbb753a36b48788f774140deb56f3f_1]**

Evolus announces positive trial data for Evolysse™ Sculpt

Evolus (EOLS)